Ixico Regulatory News (IXI)

IXICO plc

("IXICO" or the "Company")

Notice of results

Analyst and Investor briefings

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, will announce its audited Final Results for the year ended 30 September 2020 on Wednesday 2 December 2020.

Analyst briefing

A briefing open to analysts will take place remotely via video conference call on Wednesday 2 December 2020 at 1.00pm (GMT). If you would like the details of this call please contact Walbrook PR on ixico@walbrookpr.com

Investor briefing

IXICO plc will be hosting a live online presentation open to all investors on Wednesday 2 December at 3.30pm (GMT). The presentation will be delivered by Giulio Cerroni, Chief Executive Officer, Grant Nash, Chief Financial Officer and Lammert Albers, Chief Commercial Officer. The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on the recent developments and additionally providing an update on the business. The presentation will be hosted through the digital platform Investor Meet Company.

Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link: https://www.investormeetcompany.com/ixico-plc/register-investor

For those investors who have already registered and added to meet the Company, they will automatically be invited. Questions can be submitted pre-event via your Investor Meet Company dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will aim to address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

For further information please contact:

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IxicOplc